{"product_id":"caredx-pestle-analysis","title":"CareDx PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political shifts, reimbursement trends, and tech innovation shape CareDx’s outlook with our targeted PESTLE Analysis—concise, evidence-based, and strategic. Ideal for investors and planners, the full report delivers actionable insights and editable charts; purchase now to download the complete analysis instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy and reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational health policies shape transplant coverage and diagnostics reimbursement, influencing uptake across ~39,000 US transplants in 2023 (OPTN) and global post-transplant monitoring demand. Changes to Medicare, Medicaid and single-payer elements in core markets can accelerate or constrain test adoption and revenue visibility for companies like CareDx. Policy stability reduces pricing uncertainty and supports multi-year contracting, while shifts to value-based care—aiming to cut readmissions and graft loss—favor diagnostics that prevent costly failures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic funding for transplantation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment budgets shape testing volumes and care pathways: the US performs roughly 40,000 solid-organ transplants annually (OPTN), so increases in organ procurement and transplant-center funding boost demand for CareDx diagnostics and monitoring. Austerity or budget reprioritization can slow transplant placements and test renewals, reducing recurring revenue. Public-private pilot programs increasingly validate clinical utility and expand access, creating adoption catalysts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory diplomacy and trade\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCareDx's cross-border sourcing of reagents and instruments depends on trade relations, with applied US tariff averages around 3.5% (WTO) affecting input costs. Tariffs, export controls and customs delays—often adding days to weeks to delivery—can inflate timelines and working capital needs. Regulatory harmonization initiatives in 2024 (e.g., ICH and regional mutual recognition talks) can simplify multi-country launches, while 2023–24 geopolitical tensions raised supply-risk premia, pushing multi-vendor strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment research priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment grants (NIH FY2024 appropriation ~49 billion) and targeted precision-medicine funding can underwrite CareDx evidence generation for transplant outcomes; multi-year grant cycles shape the cadence of clinical studies and publications, while policymakers focused on cutting US healthcare costs (national health expenditures ~4.9 trillion in 2024, CMS projection) favor rejection surveillance tools that reduce readmissions and costs. Priority designations and real-world data programs can accelerate evaluations and reimbursement pathways.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrants underwrite trials and registries\u003c\/li\u003e\n\u003cli\u003eFunding cycles dictate publication cadence\u003c\/li\u003e\n\u003cli\u003eCost-reduction policy aligns with surveillance tools\u003c\/li\u003e\n\u003cli\u003ePriority designations speed real-world evaluations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePandemic and public health readiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppandemic-era public health emergencies refocus political priorities and hospital operations as seen when the us covid-19 emergency ended may who its global altering resource allocation for transplant diagnostics. testing utilization often reprioritizes during surges reducing routine volume while eua-like frameworks allow rapid methodological changes validation. post-crisis reviews have institutionalized remote workflows that support decentralized diagnostics telehealth-enabled sample management.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic health emergency dates: US May 11, 2023; WHO May 5, 2023\u003c\/li\u003e\n\u003cli\u003eSurge-driven reprioritization reduces routine testing volumes\u003c\/li\u003e\n\u003cli\u003eEUA frameworks enable rapid method adaptation\u003c\/li\u003e\n\u003cli\u003eRemote workflows institutionalized, aiding decentralized diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppandemic-era\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shifts boost \u003cstrong\u003e~40,000\u003c\/strong\u003e US transplants; tariffs, funding reframe risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNational health policy and payor changes (Medicare\/Medicaid) drive adoption across ~40,000 US transplants (OPTN 2023) and affect reimbursement visibility. Trade frictions (WTO avg tariffs ~3.5%) and 2023–24 geopolitical strains raise input-cost and supply-timing risks. Public funding (NIH ~$49B FY2024) and US NHE ~$4.9T (2024) favor surveillance tools that lower readmissions; PHEs (US May 11, 2023; WHO May 5, 2023) shift operational priorities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransplants\u003c\/td\u003e\n\u003ctd\u003e~40,000 (2023 OPTN)\u003c\/td\u003e\n\u003ctd\u003eBase demand for diagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding\u003c\/td\u003e\n\u003ctd\u003eNIH ~$49B (FY2024)\u003c\/td\u003e\n\u003ctd\u003eTrial\/evidence support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCosts\u003c\/td\u003e\n\u003ctd\u003eTariffs ~3.5% (WTO avg)\u003c\/td\u003e\n\u003ctd\u003eInput price\/supply risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolicy\u003c\/td\u003e\n\u003ctd\u003eUS NHE ~$4.9T (2024)\u003c\/td\u003e\n\u003ctd\u003eFavors cost-saving tools\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic health\u003c\/td\u003e\n\u003ctd\u003ePHE end US 11-May-2023; WHO 5-May-2023\u003c\/td\u003e\n\u003ctd\u003eVolume\/operation shifts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental and Legal forces uniquely affect CareDx, with data-backed trends and scenario-oriented insights to identify risks and opportunities for executives, investors and strategists; formatted for seamless inclusion in plans and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clean, categorized PESTLE summary of CareDx that speeds risk assessment and decision-making, is editable for local context or business line, and is presentation-ready and easily shareable across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer mix and pricing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial versus public payer mix materially drives realized price per AlloSure test, with greater commercial share yielding higher average reimbursement while Medicare\/Medicaid compress realized revenue. Payer cost-containment and expanded prior authorization in 2024 tightened utilization, slowing test growth. Published evidence that AlloSure reduces biopsies and hospitalizations underpins higher pricing. Tiered contracts and outcomes-based models are being used to defend margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital budget constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTransplant centers face tight capital and operating budgets as US transplant volume reached about 44,000 procedures in 2023, intensifying resource pressure. Economic slowdowns commonly defer instrument upgrades and new program adoption, while CMS moves to value-based and bundled payments increase demand for diagnostics that prevent costly complications. Consequently, robust value dossiers and health-economic models (commonly judged against $100,000–$150,000\/QALY thresholds) are critical in procurement cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroeconomic volatility pressures CareDx as inflation—US CPI ~3.4% in 2024—raises lab labor, reagent and logistics costs, compressing margins; currency swings complicate translation of roughly one-third of revenue and increase costs for imported inputs; higher interest rates (Federal funds ~5.25% mid‑2024) raise R\u0026amp;D and M\u0026amp;A financing costs; rigorous scenario planning preserves gross margin and tests patient affordability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket size and growth of transplants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDonor availability and a US waitlist of ≈100,000 set addressable volume while roughly 43,000 US transplants and ≈150,000 global procedures annually (2023) define procedure base; advances in preservation and allocation can lift counts, economic growth expands transplant capacity in emerging markets, and long‑term graft monitoring drives recurring revenue per patient through lifetime surveillance and diagnostics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAddressable volume: waitlist ≈100,000\u003c\/li\u003e\n\u003cli\u003eProcedure base: US ≈43,000; global ≈150,000 (2023)\u003c\/li\u003e\n\u003cli\u003eGrowth drivers: preservation, allocation, infrastructure\u003c\/li\u003e\n\u003cli\u003eRevenue: recurring monitoring over graft life\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition and consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDiagnostic incumbents and new entrants both pressure pricing and share for CareDx, while hospital and payer consolidation increases buyers' negotiating leverage; approximately 40,000 solid-organ transplants occur in the US annually, underpinning volume value for diagnostics. Partnerships with transplant networks can lock in recurring volumes, and M\u0026amp;A can expand CareDx platforms rapidly but raises integration and execution risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePricing pressure: incumbents vs new entrants\u003c\/li\u003e\n\u003cli\u003eBuyers' leverage: hospital\/payer consolidation\u003c\/li\u003e\n\u003cli\u003eVolume lock: ~40,000 US transplants\/year\u003c\/li\u003e\n\u003cli\u003eM\u0026amp;A: faster scale, higher integration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shifts boost \u003cstrong\u003e~40,000\u003c\/strong\u003e US transplants; tariffs, funding reframe risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCommercial payer mix drives AlloSure pricing; Medicare\/Medicaid compresses realized revenue, and 2024 prior authorization slowed utilization. US transplant volume ~44,000 (2023) with waitlist ≈100,000 sets addressable market. Inflation (~3.4% 2024) and Fed funds ≈5.25% raise costs; ~33% revenue from international exposes FX risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS transplants (2023)\u003c\/td\u003e\n\u003ctd\u003e≈44,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWaitlist\u003c\/td\u003e\n\u003ctd\u003e≈100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflation (2024 CPI)\u003c\/td\u003e\n\u003ctd\u003e≈3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (mid‑2024)\u003c\/td\u003e\n\u003ctd\u003e≈5.25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue share\u003c\/td\u003e\n\u003ctd\u003e≈33%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCareDx PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact CareDx PESTLE Analysis you’ll receive after purchase—fully formatted and ready to use. It contains the same political, economic, social, technological, legal and environmental assessments, structure and visuals as the downloadable file. No placeholders or teasers—this is the final, professionally prepared document delivered immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162514764153,"sku":"caredx-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/caredx-pestle-analysis.png?v=1762702050","url":"https:\/\/portersfiveforce.com\/products\/caredx-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}